Zelira Therapeutics has announced the University of Western Australia team that undertook a double-blind, placebo-controlled, crossover trial of its ZTL-101 (Zenivol) treatment for chronic insomnia patients has had the results published in peer-reviewed journal Sleep.

The results of the trial, undertaken at the university’s Centre for Sleep Science and published earlier this year, showed patients saw a significant decrease in insomnia after using Zenivol for two weeks relative to a placebo. Chronic insomnia is present in six to 15% of the population.

Chronic insomnia is present in six to 15% of the population.

Zenivol was launched in Australia in September last year and is available through the TGA’s Special Access and Authorised Prescriber Schemes.

Zelira CEO Dr Oludare Odumosu said: “Physicians and patients often ask for published, peer-reviewed data from a double-blind, placebo-controlled, crossover study.

“With this publication… we can confidently say ‘here you have the first scientific peer reviewed publication for a cannabinoid medicine to treat insomnia’.”

“Zelira is committed to taking Zenivol through registration approval as the world’s first fully validated and approved cannabinoid treatment for chronic insomnia.”

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...